Clarient Launches New Gene Mutation Test To Help Select Therapy For Non-Small Cell Lung Cancer

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, announced the launch of a new gene mutation test that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The test, called epidermal growth factor receptor (EGFR) mutation, has been validated as a laboratory-developed test and is now available to physicians and their patients.